Redeye sees an unrecognized business with stable sales development, ongoing geographical expansion, and good cost control. Following the report, which came in line more or less with our expectations, we reiterate our stance on AroCell flying under the radar with its product portfolio. At current levels, the stock market fails to see the core-business developments since the 2021 FDA withdrawal of TK210 ELISA and the cheapness of the stock.